Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.

@article{Kelly2014UmeclidiniumBA,
  title={Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.},
  author={Emer M Kelly},
  journal={Expert review of clinical pharmacology},
  year={2014},
  volume={7 4},
  pages={403-13}
}
Drugs from the two major classes of bronchodilator; umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting β2 agonist (LABA), have been combined in a single inhaler device for once-daily use in chronic obstructive pulmonary disease (COPD). These drugs have been proven safe and well tolerated in patients with COPD and show an enhanced improvement in FEV1 when compared to either drug in isolation and when compared with an established LAMA drug. In this article, we… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-3 of 3 extracted citations

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).

The Cochrane database of systematic reviews • 2017
View 2 Excerpts
Highly Influenced

Positioning new pharmacotherapies for COPD

International journal of chronic obstructive pulmonary disease • 2015

Similar Papers

Loading similar papers…